Skip to Content
Merck
  • Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits.

Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits.

Molecular psychiatry (2014-07-16)
K Brami-Cherrier, A Anzalone, M Ramos, I Forne, F Macciardi, A Imhof, E Borrelli
ABSTRACT

Alterations of the dopaminergic system are associated with the cognitive and functional dysfunctions that characterize complex neuropsychiatric disorders. We modeled a dysfunctional dopaminergic system using mice with targeted ablation of dopamine (DA) D2 autoreceptors in mesencephalic dopaminergic neurons. Loss of D2 autoreceptors abolishes D2-mediated control of DA synthesis and release. Here, we show that this mutation leads to a profound alteration of the genomic landscape of neurons receiving dopaminergic afferents at distal sites, specifically in the prefrontal cortex. Indeed, we observed a remarkable downregulation of gene expression in this area of ~2000 genes, which involves a widespread increase in the histone repressive mark H3K9me2/3. This reprogramming process is coupled to psychotic-like behaviors in the mutant mice. Importantly, chronic treatment with a DA agonist can revert the genomic phenotype. Thus, cortical neurons undergo a profound epigenetic reprogramming in response to dysfunctional D2 autoreceptor signaling leading to altered DA levels, a process that may underlie a number of neuropsychiatric disorders.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Clozapine
Clozapine, European Pharmacopoeia (EP) Reference Standard
USP
Clozapine, United States Pharmacopeia (USP) Reference Standard
Clozapine for peak identification, European Pharmacopoeia (EP) Reference Standard